8-K: Windtree Therapeutics Inks Licensing Deal with Lees Pharmaceutical, Amends Agreements with Philip Morris

Windtree Therapeutics has entered into a licensing agreement with Lees Pharmaceutical for its cardiovascular products in several Asian markets and amended agreements with Philip Morris related to its former pulmonary care platform.

Summary

• Windtree Therapeutics has granted Lees Pharmaceutical exclusive rights to develop and commercialize its cardiovascular products in a large Asian territory.
• The agreement includes potential upfront and milestone payments totaling up to $138.35 million, plus royalties on sales.
• Windtree will receive a low double-digit percentage of Lees' sublicense income.
• Royalties range from low single-digit to low double-digit percentages, depending on the product and are subject to reductions based on generic competition.
• Lees will be responsible for all development, manufacturing, regulatory approval, and commercialization costs in the licensed territory.
• Windtree retains final decision rights over clinical protocols.
• Windtree also secured rights to use any intellectual property developed by Lees for development outside the licensed territory.
• Windtree amended agreements with Philip Morris USA and Philip Morris Products related to its former pulmonary care platform.
• These amendments involve payments to Philip Morris totaling up to $2.2 million, contingent on Windtree receiving milestone payments from Lees and other financing.
• The amendments also extinguish previous quarterly payment obligations between the parties.

Sentiment

Score: 7

Explanation: The licensing agreement with Lees is a positive development, providing potential revenue and market expansion. However, the dependence on Lees' success and the contingent payments to Philip Morris introduce some uncertainty.

Positives

• The licensing agreement with Lees Pharmaceutical provides a significant opportunity for Windtree to expand its market reach into Asia.
• The potential for $138.35 million in milestone payments and royalties could provide substantial revenue for Windtree.
• Lees will bear the costs of development, manufacturing, and commercialization in the licensed territory, reducing Windtree's financial burden.
• The amendments with Philip Morris extinguish previous payment obligations, simplifying the financial structure.
• Windtree retains rights to use Lees' intellectual property for development outside the licensed territory.

Negatives

• The royalty rates are subject to reduction by as much as 50% in a given country based on generic competition.
• Windtree is dependent on Lees' success in developing and commercializing the products in the licensed territory.
• The milestone payments from Philip Morris are contingent on Windtree receiving payments from Lees and other financing, creating some uncertainty.
• The agreement with Lees is effective as of January 7, 2023, which is a year prior to the announcement date.

Risks

• The success of the licensing agreement with Lees depends on their ability to navigate regulatory hurdles and successfully commercialize the products.
• Generic competition could significantly reduce royalty payments.
• The milestone payments from Philip Morris are contingent on Windtree receiving payments from Lees and other financing, creating some uncertainty.
• There is a risk that Lees may not be able to successfully develop and commercialize the products in the licensed territory.
• The agreement with Lees is effective as of January 7, 2023, which is a year prior to the announcement date, which could indicate a delay in the announcement.

Future Outlook

Windtree anticipates receiving milestone payments from Lees, which will be used to fund payments to Philip Morris. The company expects to benefit from the commercialization of its products in the licensed territory by Lees.

Management Comments

• The document does not contain any direct quotes from management.

Industry Context

This announcement reflects a trend in the pharmaceutical industry where companies license their products to partners in specific regions to expand market reach and share development costs. The focus on cardiovascular treatments aligns with the growing global burden of heart disease.

Comparison to Industry Standards

• Licensing agreements are common in the pharmaceutical industry, particularly for companies seeking to expand into new geographic markets.
• The structure of the deal with Lees, including upfront payments, milestone payments, and royalties, is typical of such agreements.
• The royalty rates, ranging from low single-digit to low double-digit percentages, are within the typical range for pharmaceutical licensing deals.
• The payments to Philip Morris are structured to be contingent on Windtree's success with the Lees agreement, which is a common risk-sharing approach.

Stakeholder Impact

• Shareholders may view the licensing agreement with Lees as a positive step towards revenue generation and market expansion.
• Employees may see this as a positive development for the company's future.
• Customers in the licensed territory may benefit from access to Windtree's products.
• Suppliers may see increased demand for their products as Lees begins commercialization.
• Creditors may view the potential for increased revenue as a positive sign for the company's financial stability.

Next Steps

• Lees will begin development and commercialization activities in the licensed territory.
• Windtree will monitor Lees' progress and provide support as needed.
• Windtree will seek to secure the necessary financing to meet its obligations to Philip Morris.
• Windtree will continue to develop its products for markets outside the licensed territory.

Key Dates

Keywords

licensing agreement, cardiovascular, istaroxime, rostafuroxin, SERCA2a activators, Lees Pharmaceutical, Philip Morris, milestone payments, royalties, Asia